What are the names of the three vaccine companies Eli Lilly is acquiring, and how much is Lilly paying for each?

Eli Lilly is acquiring Curevo Vaccine for up to $1.5 billion, LimmaTech Biologics for up to $780 million, and Vaccine Company for up to $1.6 billion. The total acquisition cost is up to $3.8 billion. Lilly did not disclose the upfront cash payments for each company.

What vaccine candidates do the three acquired companies bring to Eli Lilly’s pipeline?

Curevo Vaccine brings a midstage vaccine candidate against shingles; LimmaTech Biologics brings early-stage vaccine candidates targeting bacteria; and Vaccine Company brings a preclinical vaccine candidate against Epstein-Barr virus (EBV) and other viruses.

Eli Lilly to Acquire Three Vaccine Firms in 'Power Move'

May 26, 2026

Eli Lilly plans to spend up to $3.8 billion to acquire three vaccine makers, expanding its immunology portfolio with candidates targeting shingles, bacteria, and viruses.

cen

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026